All In Biotech

Drug Trial Radar · NCT04640623

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

220

Actual

Start

Dec 18, 2020

Primary completion

Jul 3, 2025

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).

Conditions

  • Urinary Bladder Neoplasms

Interventions

  • TAR-200Drug

    TAR-200 will be administered transuretherally.

  • CetrelimabBiological

    Cetrelimab will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohorts 1, 2, and 3: Overall Complete Response (CR) RateTime frame: From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months)
  2. Cohort 4: Disease-free Survival (DFS)Time frame: From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months)

Locations

144 sites in 16 countries. Site status is shown where the registry gives one.

  • Del Sol Research Management, LLC

    Tucson, Arizona

  • University of Southern California

    Los Angeles, California

  • Genesis Healthcare Partners - Genesis Research Greater Los Angeles

    Sherman Oaks, California

  • The Urology Center of Colorado

    Denver, Colorado

  • Foothills Urology - Golden Off

    Golden, Colorado

  • DuPage Medical Group

    Lisle, Illinois

  • Urology of Indiana

    Greenwood, Indiana

  • Wichita Urology Group

    Wichita, Kansas

  • Michigan Institute of Urology

    Troy, Michigan

  • NYU Langone Health

    New York, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • Associated Medical Professionals

    Syracuse, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • The Urology Group

    Cincinnati, Ohio

  • Urologic Consultants of Southeastern Pennsylvania

    Bala-Cynwyd, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Urology Associates, PC

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Urology Austin

    Austin, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Urology San Antonio Research

    San Antonio, Texas

  • Spokane Urology

    Spokane, Washington

  • Flinders Medical Centre

    Bedford Park, Australia

  • Eastern Health Research

    Box Hill, Australia

  • Macquarie University Hospital

    Sydney, Australia

  • AZ Sint-Lucas Brugge

    Assebroek, Belgium

  • AZ Sint-Jan Brugge

    Bruges, Belgium

  • Hopital Erasme

    Brussels, Belgium

  • Algemeen ziekenhuis Maria Middelares

    Ghent, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Algemeen Ziekenhuis Delta

    Roeselare, Belgium

  • AZ Nikolaas

    Sint-Niklaas, Belgium

  • Exdeo Clinical Research Inc

    Abbotsford British Columbia, British Columbia, Canada

  • William Osler Health System

    Brampton, Ontario, Canada

  • Princess Margaret Hospital- UHN

    Toronto, Ontario, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Universite de Sherbrooke

    Sherbrooke, Quebec, Canada

  • Hopital Pellegrin CHU Bordeaux

    Bordeaux, France

  • Polyclinique Bordeaux Nord Acquitaine

    Bordeaux, France

  • CHU Grenoble

    Grenoble, France

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.